Table 3. Multivariate analyses for brain metastasis-specific progression-free survival.
| Factor | BMPFS | ||
|---|---|---|---|
| Hazard ratio | 95% CI | p-value | |
| Treatment | 0.001 | ||
| WBRT alone | Reference | ||
| Surgery | 0.31 | 0.11-0.82 | 0.018 |
| SRS | 1.67 | 0.96-2.91 | 0.068 |
| SRS+Surgery | 0.38 | 0.14-1.03 | 0.057 |
| PR | 0.029 | ||
| Positive | Reference | ||
| Negative | 0.45 | 0.22-0.92 | |
| Subtype | 0.645 | ||
| TN | Reference | ||
| HR+HER2- | 0.68 | 0.31-1.52 | 0.349 |
| HR+HER2+ | 0.79 | 0.36-1.74 | 0.554 |
| HR-HER2+ | 0.66 | 0.31-1.40 | 0.277 |
| No. of metastases in brain | 0.016 | ||
| Multiple (≥5) | Reference | ||
| Single | 0.73 | 0.36-1.45 | 0.364 |
| Oligometastasis (2-4) | 0.43 | 0.24-0.77 | 0.004 |
BMPFS=brain metastasis-specific progression-free survival; CI=confidence interval; WBRT=whole brain radiotherapy; SRS=stereotactic radiosurgery; PR=progesterone receptor; TN=triple-negative; HR=hormone receptor; HER2=human epidermal growth factor receptor 2.